Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ubamatamab with or without additional agents in platinum-resistant ovarian cancer
NCT06787612Phase 2Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- May 2025
- Primary completion
- Jun 2028
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 2, open-label trial of ubamatamab in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (6 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Objective Response Rate at 3 years. Started May 2025; status: recruiting.
02
Drugs
ubamatamab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT06787612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06787612.